Press Release Details

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present a corporate summary and an update regarding the Company's clinical programs at the following investor conferences in New York:

• Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 2:00 p.m. Eastern time
• Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 2:10 p.m. Eastern Time
• JMP Securities Healthcare Conference on Tuesday, September 27, 2011 8:30 a.m. Eastern Time

Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at www.BioCryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910

Source: BioCryst Pharmaceuticals

News Provided by Acquire Media